sufentanil has been researched along with Adverse Drug Event in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
Chen, L; Feng, X; Liao, Z; Yang, P; Ye, L; Zhou, R | 1 |
Aschenbrenner, DS | 1 |
1 review(s) available for sufentanil and Adverse Drug Event
Article | Year |
---|---|
Comparison of oxycodone and sufentanil in patient-controlled intravenous analgesia for postoperative patients: a meta-analysis of randomized controlled trials.
Topics: Analgesia, Patient-Controlled; Drug-Related Side Effects and Adverse Reactions; Humans; Oxycodone; Pain, Postoperative; Randomized Controlled Trials as Topic; Sufentanil | 2023 |
3 other study(ies) available for sufentanil and Adverse Drug Event
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Approval of New Opioid Raises Concerns.
Topics: Administration, Sublingual; Analgesics, Opioid; Chronic Pain; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Opioid-Related Disorders; Sufentanil; United States; United States Food and Drug Administration | 2019 |